Does psychedelic microdosing improve mood or focus?

What does microdosing mean?

Microdosing generally refers to taking small amounts of a psychedelic with the intention of avoiding a full psychedelic experience. There is no single product or universally agreed threshold, and an amount that feels subtle to one person may be noticeable to another. Psilocybin and LSD are different compounds; studies of one cannot automatically answer questions about the other. This guide does not provide a regimen or advice on obtaining substances.14

What did placebo-controlled studies find?

In a 2022 double-blind study, 34 people intending to microdose psilocybin-containing mushrooms took part in active and placebo conditions. Researchers observed some noticeable acute effects, but no evidence of improved wellbeing, creativity or cognitive performance on the measures tested; a few measures shifted toward poorer performance. Expectations and correctly guessing the condition complicate interpretation. The small study cannot exclude subtle effects or establish long-term safety.

In a separate study, 56 healthy adults were assigned repeated low amounts of LSD or placebo over a short period. The higher tested amount produced modest subjective effects but did not improve mood or most measured tasks. This does not rule out benefits in other populations or conditions.12

Can a short-term lift be different from lasting change?

Yes. A 2023 New Zealand trial assigned 80 healthy adult men to a defined LSD preparation or placebo for six weeks. On days when participants received the study substance, daily self-ratings of energy, happiness and feeling creative showed a more positive pattern in the LSD group than the placebo group. The researchers adjusted for expectations measured before the study, but some participants correctly guessed their group, which could still influence self-reports.

At the six-week assessment, the study did not find convincing changes in its longer-term mood questionnaires or cognitive tests. Four participants in the LSD group stopped the study medication after anxiety associated with overstimulation. A later creativity analysis of the same participants did not find a clear improvement on the creativity tasks tested, despite reports of feeling more creative. Feeling creative and performing better on a particular task are different outcomes; neither exhausts what creativity means.

This small trial in healthy men cannot establish how women, people with depression or other groups would respond, or whether effects persist with longer use. It was funded by New Zealand’s Health Research Council and individual donors; some authors disclosed research funding from a psychedelic-drug company for further work.67

Why do anecdotes and trials differ?

Personal experiences are real, but changes after starting a practice can also reflect expectations, other changes in life or natural variation. A placebo comparison helps separate these possibilities, though participants sometimes notice a drug effect and correctly guess their group. A 2026 review found no consistent immediate benefit for depression, anxiety or stress measures in the small randomized studies it could combine; the evidence remains inconclusive. Healthy-volunteer findings are not trials of treatment for a diagnosed condition.

A 2021 study asked people who already intended to microdose to take part in a self-blinded comparison in their own settings; 191 completed the main study period. Some psychological measures improved over time in both active and placebo groups, and the planned comparisons found no statistically significant difference between groups on the psychological scales after the study period. This illustrates why improvement alone cannot identify its cause. It does not prove every reported benefit is placebo or that the groups were equivalent.

Participants used their own substances without clinical supervision, and researchers could not verify their identity, purity or strength. That makes the study more reflective of some real-world practices but less controlled than a clinical trial; it also did not establish safety or test a treatment for depression.35

Risks and the difference from therapy trials

A low amount is not automatically imperceptible or risk-free. The US National Center for Complementary and Integrative Health lists potential problems including anxiety, sleep disturbance, physical discomfort and impaired focus; longer-term safety remains unclear. Product identity and strength can be uncertain, and legal rules vary by jurisdiction. Do not replace prescribed mental-health care or stop medication on the basis of anecdotes. For supervised research using a different treatment approach, see the psilocybin profile and the psychedelics hub.

NCCIH also states that psilocybin is not safe for people with psychotic conditions such as schizophrenia or schizoaffective disorder, or severe forms of bipolar disorder. This warning concerns psilocybin; the safety of microdosing remains uncertain.4